Press release
Rising Diabetes Prevalence Fuels Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market: A Key Driver Powering Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth In 2025
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics
What Is the Current Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Size and Its Estimated Growth Rate?
In recent years, the market size for therapeutics and diagnostics of exocrine pancreatic insufficiency (EPI) has seen robust growth. The market, which stands at $5.69 billion in 2024, will escalate to $6.17 billion in 2025, marking a compound annual growth rate (CAGR) of 8.4%. Factors such as a heightened incidence of contributing conditions, improvements in diagnostic devices, advancements in pharmaceuticals, and expanded global access to healthcare have spearheaded the growth during the historical period.
The market size for therapeutics and diagnostics of exocrine pancreatic insufficiency (EPI) is forecasted to witness substantial growth in the coming years. It is projected to expand to $8.32 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.8%. The growth in the projected period is due to factors such as telemedicine and remote monitoring, data analytics and artificial intelligence, patient education and support initiatives, along with regulatory alterations and reimbursement policies. Key trends for the forecast period involve personalized treatment strategies, the creation of new therapies, minimally invasive diagnostics, and cooperative care models.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12992
How Are Emerging Segments Shaping the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Landscape?
The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market covered in this report is segmented -
1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
Which Growth Factors Are Influencing Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Expansion?
The projected rise in the number of diabetic individuals is anticipated to fuel expansion in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Diabetes is identified as a persistent metabolic disorder, leading to high sugar levels over an extended period due to the body's incapability to appropriately generate or absorb insulin. An EPI therapy, mainly employing pancreatic enzyme replacement therapy (PERT) contributes to better nutrient assimilation in diabetic and EPI patients, thereby enhancing the control of their blood sugar levels. As an example, in June 2024, according to the National Health Service (NHS England), a public healthcare system in the UK, there was a 18% rise in pre-diabetic cases from 3,065,825 in 2022 to 3,615,330 in 2023. Particularly in the under 40 demographic, the surge was almost 25%, moving from 173,166 in 2022 to 216,440 in 2023. Thus, the expansion of the diabetic population forms a primary factor in escalating the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. The anticipated surge in gastrointestinal ailments is set to further augment the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. These ailments have a significant impact on the gastrointestinal tract, which encompasses the organs involved in digestion. EPI therapeutics and diagnostics play a vital role in managing these diseases by rectifying the fundamental enzyme deficiency and facilitating proper digestion of nutrients. For instance, in June 2023, as per Crohn's and Colitis Canada, a non-profit organization from Canada, an estimated 322,600 Canadians were believed to be living with inflammatory bowel diseases (IBD) in 2023, about 0.82% of the population. Given the enduring prevalence of IBD, it is projected that by 2035, nearly 1.1% or 1 in every 91 people in the country, equivalent to around 470,000 Canadians, will be diagnosed with IBD. Consequently, the growth of the EPI therapeutics and diagnostics market is expected to be driven by the rise in gastrointestinal diseases.
Who Are the Dominant Players Across Different Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Segments?
Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.
What Are the Latest Developing Trends in the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
Leading enterprises active in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics sector are resorting to strategic partnerships as a means to further technical integration and enlarge their market presence. Such partnerships often entail a cooperative relationship between two or more entities pooling their resources, skills and strategies to achieve shared targets or purposes. A case in point is the revelation of preliminary results from the Phase 1 clinical trial of CDX-7108 in February 2023 by Codexis, Inc., an American protein engineering firm, and Nestlé Health Science, a Swiss-based nutrition science company. This investigational therapy targeted at EPI treatment may soon open new possibilities for enhanced treatment options for patients struggling with EPI following the successful outcome of the Phase 1 trial.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report
Which Geographic Regions Are Expected to Dominate the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market in the Coming Years?
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
2. What is the CAGR expected in the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
3. What Are the Key Innovations Transforming the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Industry?
4. Which Region Is Leading the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rising Diabetes Prevalence Fuels Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market: A Key Driver Powering Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Growth In 2025 here
News-ID: 4023151 • Views: …
More Releases from The Business Research Company
Global Double-Sided Masking Tapes Market Expansion at 7.8% CAGR, Valued at $18.4 …
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
What Are the Double-Sided Masking Tapes Market Size Forecast for 2025?
The market size of double-sided masking tapes has been experiencing consistent growth in recent years. The market will increase from a figure of $13.01 billion in 2024 to about $13.64 billion in 2025, demonstrating a compound annual growth rate…
Construction Adhesives Market on Path to Hit $18.32 Billion by 2029 at 9% CAGR
Use ONLINE30 for 30% savings on global market reports and stay on top of tariff updates, market trends, and economic shifts worldwide.
Construction Adhesives Market Outlook: What Size And CAGR Are Anticipated By 2025?
There has been a robust growth in the size of the construction adhesives market in the recent past. The market that was at $12.06 billion in 2024 is projected to rise to $12.95 billion in 2025, with a…
Future of Chromatography Resins Market: Size, Share & Forecasts to 2029
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
What Is the Projected Market Size Valuation of the Chromatography Resins Market by 2025?
In recent years, the market size of chromatography resins has experienced significant growth. Starting from a value of $2.95 billion in 2024, it is predicted to increase to $3.15 billion in 2025 with a compound annual growth…
Blow-Molded Plastics Industry Set to Achieve $128.73 Billion Milestone by 2029 | …
Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.
What Is the Long-Term Growth Forecast for the Blow-Molded Plastics Market Size 2025?
The market size of blow-molded plastics has seen constant enlargement in the previous few years. It is expected to rise from $97.17 billion in 2024 to $99.31 billion in 2025, at a compound annual growth rate (CAGR) of…
More Releases for EPI
Consumer Electronics Adoption Fuels The Silicon Epi Wafer Market: Core Growth En …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
What Will the Silicon EPI Wafer Industry Market Size Be by 2025?
Over recent years, the market size for silicon EPI wafers has seen considerable growth. Predictions indicate an increase from $1.8 billion in 2024 to $1.92 billion in 2025, representing a compound annual growth rate (CAGR) of 6.8%. Factors contributing to this historical…
Evolving Market Trends In The Silicon EPI Wafer Industry: Next-Generation Silico …
The Silicon EPI Wafer Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Silicon EPI Wafer Market Size During the Forecast Period?
In recent times, the silicon EPI wafer market has witnessed substantial growth. The market size, which stood at $1.8 billion in…
Leading Growth Driver in the Silicon EPI Wafer Market in 2025: Consumer Electron …
What industry-specific factors are fueling the growth of the silicon epi wafer market?
The silicon EPI wafer market is expected to experience significant growth due to the increased use of consumer electronics products. Consumer electronics (CE) refers to electronic devices specifically designed for everyday use by consumers for non-commercial or professional purposes. Silicon wafers, which are semiconductors, are used in the manufacture of microchips and chips for these electronic devices. For…
EPI Invests $1 Million USD in the EPI Data Center Futurist Scholarship Program
Singapore (15 June 2023) - EPI, the global leader in data center training, audit & certification, is proud to announce the launch of the EPI Data Center Futurist Scholarship program, accompanied by a significant investment of one (1) million US-Dollar. This transformative initiative aims to provide aspiring professionals with the resources and support they need to acquire the specialized knowledge and skills necessary for success in the dynamic data…
Epi Wafer Market to Surpass Valuation of US$ 5.8 Bn by 2030 with Rising Demand f …
The global Epi Wafer market is estimated to attain a valuation of US$ 5.8 billion by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 6% during the forecast period, 2021-2031.
The key objective of the TMR report is to offer a complete assessment of the global market including major leading stakeholders of…
Exocrine Pancreatic Insufficiency (EPI) Therapeutics- Pipeline Analysis
Exocrine pancreatic insufficiency (EPI) is the inability of pancreas to produce enough enzymes for the proper breakdown and absorption of nutrients. The common causes of EPI are damage to pancreas, inflammation of pancreas, pancreatic surgery, and inherited disorders like Crohn’s disease and celiac disease.
Download the sample report at: https://www.pharmaproff.com/request-sample/1024
Some symptoms observed during EPI are pain or tenderness in belly, bad-smelling bowel movements, gas, diarrhea and feeling of fullness. EPI…
